Waltham, MA, United States of America

Anu Gupta

This inventor holds 3 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Deciphera Pharmaceuticals, LLC. Active years: 2024-2026.

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2024-2026

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Anu Gupta: Innovator in Cancer Treatment

Introduction

Anu Gupta is a prominent inventor based in Waltham, MA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development. With a total of 3 patents, Gupta is recognized for her work in combination therapies aimed at treating various cancers.

Latest Patents

Gupta's latest patents include groundbreaking therapies for the treatment of mastocytosis and gastrointestinal stromal tumors. The first patent focuses on the use of specific compounds in combination with MAPKAP pathway inhibitors for mastocytosis treatment. The second patent addresses the use of similar compounds in conjunction with MAPKAP kinase inhibitors for treating cancers, particularly c-KIT-mediated cancers such as GIST.

Career Highlights

Anu Gupta is currently employed at Deciphera Pharmaceuticals, LLC, where she continues to advance her research in oncology. Her work is pivotal in developing effective treatment options for patients suffering from challenging cancers.

Collaborations

Gupta collaborates with notable colleagues, including Daniel L Flynn and Bryan D Smith, to enhance the impact of her research and innovations.

Conclusion

Anu Gupta's contributions to cancer treatment through her innovative patents and collaborative efforts highlight her role as a leading inventor in the field. Her work continues to inspire advancements in medical therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…